UK's DoH has 'open mind' on generic substitution plans

5 March 2010

Final decisions on whether generic substitution will be introduced in England have yet to be made, the UK government has insisted, comments Tom Moberly writing for HealthcareRepublic. Responses to the current consultation (The Pharma Letters passim) on whether pharmacists in England should be allowed to switch drugs prescribed by brand to generic alternatives will inform any decision, the Department of Health said.

DoH officials stressed the point at a meeting in London last Tuesday which formed part of a series of events being conducted as part of the consultation into proposals to introduce generic substitution by pharmacists in England. Much of the event focused on how generic substitution would be implemented, rather than whether it should, leading attendees to suggest that the DoH had already made up its mind.

'This is absolutely not trying to pre-empt what the consultation may come out with,' a DoH spokeswoman said, adding: 'It is just trying to take the opportunity to get people's views on what - if ministers say we really have to squeeze every last drop out of the generic prescribing of medicines - would be the best way of doing it.' She said it was important that people raised any concerns with the DoH through the consultation process.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Generics